Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ATF4 | P18848 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7865505 | 0.84 | HPGD (0.46) | HPGDATF4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL321332 | 0.84 | HPGD (0.47) | HPGDKDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6268154 | 0.79 | VCP (0.43) | HPGDSMN1; SMN2 | |
| SCHEMBL7857644 | 0.76 | NPC1 (0.36) | HPGDATF4KDM4ENFE2L2L3MBTL1 | |
| SCHEMBL321232 | 0.76 | HPGD (0.40) | HPGDSMN1; SMN2NFE2L2 | |
| SCHEMBL7857637 | 0.74 | SMN1; SMN2 (0.42) | HPGDKDM4ECYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL21281 | 0.74 | PARP10 (0.44) | HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL18125568 | 0.74 | HPGD (0.45) | HPGDATF4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL18123508 | 0.74 | HRH3 (0.43) | HPGDCYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL3989257 | 0.73 | PARP15 (0.53) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0927555-B1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia | DAIICHI SANKYO CO LTD (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-7745481-B2 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-06-29 | — | — | US | disclosed |
| EP-0799823-B1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | DAIICHI SANKYO CO LTD (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-RE39420-E1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-12-05 | — | — | US | disclosed |
| US-6887893-B1 | Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20050014814-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED (JP) | 2005-01-20 | — | — | US | disclosed |
| US-20050004109-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED | 2005-01-06 | — | — | US | disclosed |
| EP-0927555-A1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia | Sankyo Company Limited (JP) | 1999-07-07 | — | — | EP | disclosed |
| US-5908858-A | OSTEOPOROSIS; LEUKOTRIENE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1999-06-01 | — | — | US | disclosed |
| EP-0799823-A1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1997-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014814-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | CPT1B, PYGM, PTGES2 | HPGD 29/4885ATF4 1479/4885KDM4E 3798/4885 |
| US-20050004109-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | CPT1B, PYGM, PTGES2 | HPGD 29/4885ATF4 1479/4885KDM4E 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.